Ronald Paquette

CBL , CBLB , TET 2 , ASXL 1 , and IDH 1 / 2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia

Michael A. McDevitt, Eric Hsi, John Nicoll, 2011 .

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Francisco Cervantes, Jason Gotlib, Alessandro M. Vannucchi, 2017, Journal of Hematology & Oncology.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Modern Hematology: Biology and Clinical Management

Reinhold Munker, Ronald Paquette, Erhard Hiller, 1999 .

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Michael A McDevitt, Eric Hsi, John Nicoll, 2011, Blood.